Oberg et al. designed two bispecific antibodies that bind either CD3 or the Vγ9 TCR-chain on γδ T-cells and Her2/neu expressed by pancreatic adenocarcinoma cells (221). This evidence concerns the gene ERBB2 and pancreatic adenocarcinoma.